Dr David Ribeiro

Dr David Ribeiro has extensive experience in commercialising products within chronic diseases, having previously held senior management roles at Solvay Healthcare, Encysive Pharmaceuticals and Pfizer. Most recently, David held the role of European Business Manager at Pharmaxis Pharmaceuticals Limited, a Sydney-based company with two launched products – a diagnostic test for assessing bronchial hyper-­responsiveness in asthma, and a therapeutic product designed for the chronic treatment of patients with Cystic Fibrosis.

David is a graduate of the University of Surrey, in Guildford, where he obtained a BSc in Biochemistry. He continued his studies to gain an MSc in Clinical Biochemistry, and then completed a PhD, investigating the impact of shift work on cardiovascular risk factors.

David was appointed CEO of ProAxsis in October 2015.

Dr David Ribeiro

CEO

François Martelet

Chairman François Martelet brings over 20 years of biopharma experience and a proven track record of shaping and developing businesses to deliver returns. He has broad

Ian Postlethwaite

David Moore

Head of Spin Outs & Investments, QUBIS Ltd. David is Investment Manager with QUBIS Ltd, the early stage investment fund responsible for the commercialisation of technology from The Queen’s University of Belfast.